Endoscopic dacryocystorhinostomy among the old and oldest-old populations - A case control study.


Journal

Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 13 10 2020
revised: 16 12 2020
accepted: 16 02 2021
pubmed: 22 3 2021
medline: 21 12 2021
entrez: 21 3 2021
Statut: ppublish

Résumé

Despite increased risks of nasolacrimal duct obstruction (NLDO) with age, and the continuous growth of the old population proportion, data on endoscopic dacryocystorhinostomy (eDCR) among the old is lacking. This study aims to evaluate long-term eDCR efficacy and safety in the old and oldest-old population. A retrospective case-control study of patients aged 80 ≤ (oldest-old) and 65-79 (old) compared with younger controls who underwent eDCR, between 2002 and 2017. Pre-, intra- and postoperative factors were collected using an integrated hospital-community system. Success rates were analyzed and measured at the first visit following surgery (immediate success), and after five years. Demographics, comorbidities, complications rates, and outcomes were compared between the groups. The study groups included 52 oldest-old patients (mean age 83.4 ± 3.6), 127 old patients (72.3 ± 4.14) and 142 control patients (57.8 ± 18.0). The immediate and success rates were 94.2%, 93.7% and 90.8% and five-year success rates were 80.0%, 76.6% and 80% among oldest-old, old and controls, respectively. No significant differences in success rates were found, even despite higher comorbidity rates among the study's group (96 and 92.8% vs. 63.2%, among oldest-old, old and controls respectively, p <0.001). Intra- and postoperative complications rates were low in all groups. Among older population, including oldest-old and old, eDCR safety and long-term outcomes are comparable with younger patients, suggesting that eDCR should be offered to NLDO patients, regardless of age.

Identifiants

pubmed: 33744035
pii: S0385-8146(21)00069-9
doi: 10.1016/j.anl.2021.02.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

898-904

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare no conflict of interest in connection with this article.

Auteurs

Idit Tessler (I)

Hadassah Medical School, Hebrew University, Jerusalem, Israel.

Meir Warman (M)

Hadassah Medical School, Hebrew University, Jerusalem, Israel; Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel. Electronic address: meirwarma@gmail.com.

Itai Amos (I)

Hadassah Medical School, Hebrew University, Jerusalem, Israel.

Doron Halperin (D)

Hadassah Medical School, Hebrew University, Jerusalem, Israel; Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel.

Yosef Bavnik (Y)

Hadassah Medical School, Hebrew University, Jerusalem, Israel; Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel.

Asher Milstein (A)

Hadassah Medical School, Hebrew University, Jerusalem, Israel; Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.

Yochai Shoshani (Y)

Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel; Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.

Hana Leiba (H)

Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel; Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.

Oded Cohen (O)

Hadassah Medical School, Hebrew University, Jerusalem, Israel; Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH